Brain Dead Diagnosis and Treatment Market Research Report-  Global  Forecast till 2027

Brain Dead Diagnosis & Treatment Research Report: By Diagnosis Type (Physical Examination, Blood Test, Brain Scans) Brain Scans (CT, MRI, EEG) Treatment (Medical Treatment) End User (Hospitals & Clinics, Research Laboratories) - Global Forecast till 2027

ID: MRFR/Pharma/3562-HCR | | Region: Global | 100 pages

Please note that the assessment period of report has been updated from 2017-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Scenario


Brain death is the total and irreversible loss of all brain functions and the circumstance under which the donation of vital organs most commonly takes place. Brain death occurs when a person has a catastrophic brain injury leading to total cessation of all brain function including the upper brain structure and brain stem. Brain death is not a coma or persistent vegetative state. Brain death is determined in the hospital by one or more physicians not associated with a transplantation team.


The increasing incidence of accidents and brain injury is leading to shift from treatment to oragn donation procedures are some factors responsible for the growth of the  global brain dead diagnosis and treatment market.


A brain-dead patient is supposed to have no clinical evidence of brain function upon physical examination. The examination exhibits no cranial nerve reflexes and no response to pain. The reflexes include no spontaneous respirations, oculocephalic reflex, pupillary response (fixed pupils), corneal reflex, and no response to the caloric reflex test. According to the World Health Organization estimates, neurological disorders are responsible for 4.5%-11% of all illnesses including low or high income economies. This is far higher as compared to the number of respiratory ailments, gastrointestinal disorders, or cancers, and the burden is expected to increase further over the coming years.


It is of utmost important to distinguish brain death and other states that may be difficult to differentiate from brain death, such as alcohol intoxication, chronic vegetative states, barbiturate overdose, hypoglycemia, hypothermia, coma, and sedative overdose. Few comatose patients can recover to pre-coma level of functioning, and some patients with severe irreversible neurological dysfunction will nonetheless retain some lower brain functions, such as spontaneous respiration, despite the losses of both cortex and brain stem functionality in case of anencephaly. However, limited availability of facilities and higher treatment cost may hamper the market growth during the forecast period.


The global market of brain dead diagnosis and treatment is expected to grow at a CAGR of approximately 7% during the forecast period 2017-2023.


Intended Audience



  • Brain Dead Diagnosis and Treatment Suppliers

  • Brain Dead Diagnosis and Treatment Manufacturers

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities


Segmentation


The brain dead diagnosis and treatment market is segmented on the basis of types, diagnosis, treatment, and end user.


On the basis of diagnosis, it is segmented into physical examination, blood test, brain scans, and others. Brain scan is further segmented into computerized tomography (CT) scan, magnetic resonance imaging (MRI) and electroencephalography (EEG), radionuclide angiography, cerebral arteriography, nuclear brain scanning, transcranial doppler ultrasonography


On the basis of treatment, it is segmented into medical treatment, and others.


On the basis of the end user, it is segmented into hospitals & clinics, research laboratories and others.


Regional Analysis


The global brain dead diagnosis and treatment market consists of countries namely America, Europe, Asia Pacific, and the Middle East.


North America dominated the global brain dead diagnosis and treatment market owing to the increasing healthcare expenditure. In the United States, if the patient is at or near death, the hospital must notify a transplant organization of the person's details and maintain the patient while the patient is being evaluated for suitability as a donor. The patient is kept on ventilator support until the organs have been surgically removed. Furthermore, increased R&D activities and the concentration of major companies have fueled the growth of the market in this region.


Europe holds the second position in the global brain dead diagnosis & treatment market owing to the government support for research & development and availability of funds for research. For instace, in countries such as Spain, Finland, Poland, Wales, Portugal, and France, everyone is automatically an organ donor after diagnosis of death on legally accepted criteria, although some jurisdictions such as Singapore, Spain, Wales, France, Czech Republic and Portugal allow opting out of the system. Elsewhere, consent from family members or next-of-kin may be mandatory for organ donation.


Asia Pacific is the fastest growing brain dead diagnosis & treatment market owing to the presence of rapidly developing healthcare technology, increasing stressful life, and high healthcare expenditure. Moreover, increasing patient population in countries such as New Zealand, Australia, drivers are asked upon application if they wish to be registered as an organ donor are likely to emerge as the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare is projected to lead the use of advanced equipment, which, in turn, may increase the market growth in this region. 


Furthermore in the Middle East & Africa the spending for healthcare was also increased. The Middle East & Africa holds the least share of the market owing to less availability of funds, limited medical facilities, and deprived political conditions in Africa.


Key Players


Some of key the players in the Global Brain dead diagnosis and Treatment Market are Fujifilm Holdings (Japan), GE Healthcare (U.S.), Siemens Healthcare(U.S.), Philips Healthcare (U.S.), Shimadzu Corporation (Japan), Toshiba Medical Systems Corporation (Japan), Carestream Health (U.S.), Nihon Kohden Corporation (Japan), Electrical Geodesics Inc. (U.S.), Masimo Corporation (U.S.), Hologic (U.S.), Esaote (Italy), and others


Research Methodology
Brain Dead Diagnosis and Treatment Market


Sources: Annual reports, Press release, White paper, and Company presentation


 



Frequently Asked Questions (FAQ) :


Brain dead diagnosis and treatment market is projected to grow at approximately 7% CAGR during the assessment period (2020-2027).

The increasing incidence of accidents and brain injuries are the major tailwinds pushing the growth of the global brain dead diagnosis and treatment market.

Limited availability of facilities and high cost of treatments are major growth detriments for the global brain dead diagnosis and treatment market.

North America holds the largest share in the global brain dead diagnosis and treatment market, followed by Europe and the Asia Pacific, respectively.

GE Healthcare (U.S.), Fujifilm Holdings (Japan), Siemens Healthcare(U.S.), Shimadzu Corporation (Japan), Philips Healthcare (U.S.), Toshiba Medical Systems Corporation (Japan), Nihon Kohden Corporation (Japan), Carestream Health (U.S.), Electrical Geodesics Inc. (U.S.), Hologic (U.S.), Masimo Corporation (U.S.), and Esaote (Italy), are some of the top players operating in the global brain dead diagnosis and treatment market.

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Brain Dead Diagnosis and Treatment Market, by Diagnosis

6.1 Introduction

6.2 Physical examination

6.2.1 Market Estimates & Forecast, 2020 – 2027

6.3 Blood test

6.3.1 Market Estimates & Forecast, 2020 – 2027

6.4 Brain scans

6.4.1 Market Estimates & Forecast, 2020 – 2027

6.4.2 Computerized tomography (CT)

6.4.2.1 Market Estimates & Forecast, 2020 – 2027

6.4.3 Magnetic resonance imaging (MRI)

6.4.3.1 Market Estimates & Forecast, 2020 – 2027

6.4.4 Electroencephalography (EEG)

6.4.4.1 Market Estimates & Forecast, 2020 – 2027

6.4.5 Radionuclide angiography

6.4.5.1 Market Estimates & Forecast, 2020 – 2027

6.4.6 Cerebral arteriography

6.4.6.1 Market Estimates & Forecast, 2020 – 2027

6.4.7 Nuclear brain scanning

6.4.7.1 Market Estimates & Forecast, 2020 – 2027

6.4.8 Transcranial doppler ultrasonography

6.4.8.1 Market Estimates & Forecast, 2020 – 2027

Chapter 7. Global Brain Dead Diagnosis and Treatment Market, by Treatment

7.1 Introduction

7.2 Medical Treatment

7.2.1 Market Estimates & Forecast, 2020 – 2027

7.3 Others

7.3.1 Market Estimates & Forecast, 2020 – 2027

Chapter 8. Global Brain Dead Diagnosis and Treatment Market, by End User

8.1 Introduction

8.2 Hospitals & Clinics

8.2.1 Market Estimates & Forecast, 2020 – 2027

8.3 Research Institute/ Labortories

8.3.2 Market Estimates & Forecast, 2020 – 2027

8.4 Others

8.4.2 Market Estimates & Forecast, 2020 – 2027

Chapter .9 Global Brain Dead Diagnosis and Treatment Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 U.S.

9.2.1.1 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 U.K

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

Chapter 10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Fujifilm Holdings

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials

11.1.4 SWOT Analysis

11.2 GE Healthcare

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Siemens Healthcare

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 Philips Healthcare

11.4.1 Company Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Shimadzu Corporation

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.6 Toshiba Medical Systems Corporation

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.7 Carestream Health

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Nihon Kohden Corporation

11.8.1 Company Overview

11.8.2 Product/Business Segment Overview

11.8.3 Financial Overview

11.8.4 Key Development

11.8.5 SWOT Analysis

11.9 Hologic

11.9.1 Company Overview

11.9.2 Product Overview

11.9.3 Financial overview

11.9.4 Key Developments

11.10 Others

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Pharmaceutical industry

Chapter 13 Appendix

LIST OF TABLES

Table 1 Brain Dead Diagnosis and Treatment Industry Synopsis, 2020 – 2027

Table 2 Brain Dead Diagnosis and Treatment Market Estimates and Forecast, 2020 – 2027, (USD Million)

Table 3 Brain Dead Diagnosis and Treatment Market by Region, 2020 – 2027, (USD Million)

Table 4 Brain Dead Diagnosis and Treatment Market by Diagnosis, 2020 – 2027, (USD Million)

Table 5 Brain Dead Diagnosis and Treatment Market by Treatment, 2020 – 2027, (USD Million)

Table 6 Brain Dead Diagnosis and Treatment Market by End Users, 2020 – 2027, (USD Million)

Table 7 North America Brain Dead Diagnosis and Treatment Market by Diagnosis, 2020 – 2027, (USD Million)

Table 8 North America Brain Dead Diagnosis and Treatment Market by Treatment, 2020 – 2027, (USD Million)

Table 9 North America Brain Dead Diagnosis and Treatment Market by End Users, 2020 – 2027, (USD Million)

Table 10 US Brain Dead Diagnosis and Treatment Market by Diagnosis, 2020 – 2027, (USD Million)

Table 11 US Brain Dead Diagnosis and Treatment Market by Treatment, 2020 – 2027, (USD Million)

Table 12 US Brain Dead Diagnosis and Treatment Market by End Users, 2020 – 2027, (USD Million)

Table 13 Canada Brain Dead Diagnosis and Treatment Market by Diagnosis, 2020 – 2027, (USD Million)

Table 14 Canada Brain Dead Diagnosis and Treatment Market by Treatment, 2020 – 2027, (USD Million)

Table 15 Canada Brain Dead Diagnosis and Treatment Market by End Users, 2020 – 2027, (USD Million)

Table 16 South America Brain Dead Diagnosis and Treatment Market by Diagnosis, 2020 – 2027, (USD Million)

Table 17 South America Brain Dead Diagnosis and Treatment Market by Treatment, 2020 – 2027, (USD Million)

Table 18 South America Brain Dead Diagnosis and Treatment Market by End Users, 2020 – 2027, (USD Million)

Table 19 Europe Brain Dead Diagnosis and Treatment Market by Diagnosis, 2020 – 2027, (USD Million)

Table 20 Europe Brain Dead Diagnosis and Treatment Market by Treatment, 2020 – 2027, (USD Million)

Table 21 Europe Brain Dead Diagnosis and Treatment Market by End Users, 2020 – 2027, (USD Million)

Table 22 Western Europe Brain Dead Diagnosis and Treatment Market by Diagnosis, 2020 – 2027, (USD Million)

Table 23 Western Europe Brain Dead Diagnosis and Treatment Market by Treatment, 2020 – 2027, (USD Million)

Table 24 Western Europe Brain Dead Diagnosis and Treatment Market by End Users, 2020 – 2027, (USD Million)

Table 25 Eastern Europe Brain Dead Diagnosis and Treatment Market by Diagnosis, 2020 – 2027, (USD Million)

Table 26 Eastern Europe Brain Dead Diagnosis and Treatment Market by Treatment, 2020 – 2027, (USD Million)

Table 27 Eastern Europe Brain Dead Diagnosis and Treatment Market by End Users, 2020 – 2027, (USD Million)

Table 28 Asia Pacific Brain Dead Diagnosis and Treatment Market by Diagnosis, 2020 – 2027, (USD Million)

Table 29 Asia Pacific Brain Dead Diagnosis and Treatment Market by Treatment, 2020 – 2027, (USD Million)

Table 30 Asia Pacific Brain Dead Diagnosis and Treatment Market by End Users, 2020 – 2027, (USD Million)

Table 31 Middle East & Africa Brain Dead Diagnosis and Treatment Market by Diagnosis, 2020 – 2027, (USD Million)

Table 32 Middle East & Africa Brain Dead Diagnosis and Treatment Market by Treatment, 2020 – 2027, (USD Million)

Table 33 Middle East & Africa Brain Dead Diagnosis and Treatment Market by End Users, 2020 – 2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Brain Dead Diagnosis and Treatment Market

Figure 3 Segmentation Market Dynamics for Brain Dead Diagnosis and Treatment Market

Figure 4 Global Brain Dead Diagnosis and Treatment Market Share, by Diagnosis 2020

Figure 5 Global Brain Dead Diagnosis and Treatment Market Share, by Treatment 2020

Figure 6 Global Brain Dead Diagnosis and Treatment Market Share, by End Users, 2020

Figure 7 Global Brain Dead Diagnosis and Treatment Market Share, by Region, 2020

Figure 8 North America Brain Dead Diagnosis and Treatment Market Share, by Country, 2020

Figure 9 Europe Brain Dead Diagnosis and Treatment Market Share, by Country, 2020

Figure 10 Asia Pacific Brain Dead Diagnosis and Treatment Market Share, by Country, 2020

Figure 11 Middle East & Africa Brain Dead Diagnosis and Treatment Market Share, by Country, 2020

Figure 12 Global Brain Dead Diagnosis and Treatment Market: Company Share Analysis, 2020 (%)

Figure 13 Fujifilm Holdings: Key Financials

Figure 14 Fujifilm Holdings: Segmental Revenue

Figure 15 Fujifilm Holdings: Geographical Revenue

Figure 16 GE Healthcare: Key Financials

Figure 17 GE Healthcare: Segmental Revenue

Figure 18 GE Healthcare: Geographical Revenue

Figure 19 Siemens Healthcare: Key Financials

Figure 20 Siemens Healthcare: Segmental Revenue

Figure 21 Siemens Healthcare: Geographical Revenue

Figure 22 Philips Healthcare: Key Financials

Figure 23 Philips Healthcare: Segmental Revenue

Figure 24 Philips Healthcare: Geographical Revenue

Figure 25 Shimadzu Corporation: Key Financials

Figure 26 Shimadzu Corporation: Segmental Revenue

Figure 27 Shimadzu Corporation: Geographical Revenue

Figure 28 Toshiba Medical Systems Corporation: Key Financials

Figure 29 Toshiba Medical Systems Corporation: Segmental Revenue

Figure 30 Toshiba Medical Systems Corporation: Geographical Revenue

Figure 31 Carestream Health.: Key Financials

Figure 32 Carestream Health: Segmental Revenue

Figure 33 Carestream Health: Geographical Revenue

Figure 34 Nihon Kohden Corporation: Key Financials

Figure 35 Nihon Kohden Corporation: Segmental Revenue

Figure 36 Nihon Kohden Corporation: Geographical Revenue

Figure 37 Hologic: Key Financials

Figure 38 Hologic: Segmental Revenue

Figure 39 Hologic: Geographical Revenue